Major depressive disorder - vortioxetine [ID583]: committee papers

Table of contents

 

1 Pre-Meeting Briefing by NICE

2 Submission from the technology manufacturer – Lundbeck

3 NICE request to the manufacturer for clarification on their submission

4 Manufacturer clarification response

5 Clinical expert personal perspective from Professor Heinz Grunze

6 Evidence Review Group report prepared by York

7 Evidence Review Group -  clarifications

8 Manufacturer factual accuracy check of Evidence Review Group report

9 Manufacturer factual accuracy check - response

This page was last updated: 10 June 2015